The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Bertil Persson, MD

Bertil Persson

Consultant

Bertil Persson, MD

BioMEL : a translational research biobank of melanocytic lesions and melanoma

Author

  • Teo Helkkula
  • Gustav Christensen
  • Christian Ingvar
  • Karolin Isaksson
  • Katja Harbst
  • Bertil Persson
  • Ingvar
  • Anna Hafström
  • Ana Carneiro
  • Viktoria Gaspar
  • Göran Jönsson
  • Kari Nielsen
Show all

Summary, in English

Introduction Diagnosing invasive cutaneous melanoma (CM) can be challenging due to subjectivity in distinguishing equivocal nevi, melanoma in situ and thin CMs. The underlying molecular mechanisms of progression from nevus to melanoma must be better understood. Identifying biomarkers for treatment response, diagnostics and prognostics is crucial. Using biomedical data from biobanks and population-based healthcare data, translational research can improve patient care by implementing evidence-based findings. The BioMEL biobank is a prospective, multicentre, large-scale biomedical database on equivocal nevi and all stages of primary melanoma to metastases. Its purpose is to serve as a translational resource, enabling researchers to uncover objective molecular, genotypic, phenotypic and structural differences in nevi and all stages of melanoma. The main objective is to leverage BioMEL to significantly improve diagnostics, prognostics and therapy outcomes of patients with melanoma. Methods and analysis The BioMEL biobank contains biological samples, epidemiological information and medical data from adult patients who receive routine care for melanoma. BioMEL is focused on primary and metastatic melanoma, but equivocal pigmented lesions such as clinically atypical nevi and melanoma in situ are also included. BioMEL data are gathered by questionnaires, blood sampling, tumour imaging, tissue sampling, medical records and histopathological reports. Ethics and dissemination The BioMEL biobank project is approved by the national Swedish Ethical Review Authority (Dnr. 2013/101, 2013/339, 2020/00469, 2021/01432 and 2022/02421-02). The datasets generated are not publicly available due to regulations related to the ethical review authority. Trial registration number NCT05446155.

Department/s

  • Dermatology and Venereology (Lund)
  • LUSCaR- Lund University Skin Cancer Research group
  • LUCC: Lund University Cancer Centre
  • Melanoma
  • Lund Melanoma Study Group
  • Surgery (Lund)
  • Melanoma Genomics
  • LU Profile Area: Light and Materials
  • Head and Neck Cancer Research Group
  • Clinical Sciences, Helsingborg

Publishing year

2024-02

Language

English

Publication/Series

BMJ Open

Volume

14

Issue

2

Document type

Journal article

Publisher

BMJ Publishing Group

Topic

  • Cancer and Oncology

Keywords

  • cancer genetics
  • dermatological tumours
  • dermatopathology
  • diagnostic imaging
  • health informatics

Status

Published

Research group

  • LUSCaR- Lund University Skin Cancer Research group
  • Lund Melanoma Study Group
  • Melanoma Genomics
  • Head and Neck Cancer Research Group

ISBN/ISSN/Other

  • ISSN: 2044-6055